Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 9/20 | 0.44 |
| ▸ | HTR2C | P28335 | 9/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7700904 | 0.85 | IDO1 (0.58) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL1503215 | 0.81 | IDO1 (0.54) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL18263307 | 0.80 | ALDH1A1 (0.41) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL18482277 | 0.80 | HTR2A (0.41) | IDO1HTR2AHTR2CKCNH2ALDH1A1 | |
| SCHEMBL1385782 | 0.79 | IDO1 (0.52) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL1116576 | 0.79 | IDO1 (0.57) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL29431834 | 0.79 | IDO1 (0.57) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL2766520 | 0.78 | CHRNA7 (0.51) | — | |
| SCHEMBL27753798 | 0.78 | PDPK1 (0.44) | — | |
| SCHEMBL11772436 | 0.78 | PKM (0.36) | IDO1AGXTDAOKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250036-B1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | SCRIPPS RESEARCH INST (US) | 2021-05-12 | — | — | EP | disclosed |
| WO-2018165520-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VPS-3, INC. (US) | 2018-09-13 | — | — | WO | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| CN-102234284-A | Fluorine-containing ticlopidine analogues, and preparation method and application thereof | JIE YAN | 2011-11-09 | — | — | CN | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-2038041-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | Myriad Genetics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007134298-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-0289881-A2 | 2-Aminoalkyl-4-benzyl-1-(2H)-phthalazinone derivatives | ASTA Medica Aktiengesellschaft (DE) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | IDO1 4505/4885AGXT 2804/4885DAO 4111/4885 |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | IDO1 4505/4885AGXT 2804/4885DAO 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.